Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12444335 | 0.90 | HTT (0.40) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12444361 | 0.89 | ALDH1A1 (0.37) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL22719925 | 0.89 | EGLN2 (0.41) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL13577624 | 0.88 | EGLN1 (0.40) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL29829420 | 0.88 | SMPD1 (0.45) | SMPD1HTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1503272 | 0.87 | NPC1 (0.52) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL1503203 | 0.86 | L3MBTL1 (0.40) | ALDH1A1KDM4ELMNAMAPTEGLN1 | |
| SCHEMBL1503088 | 0.86 | HDAC6 (0.40) | SMPD1HTTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL1503184 | 0.85 | MAOB (0.44) | HTTALDH1A1SMN1; SMN2KDM4ELMNA | |
| SCHEMBL22719946 | 0.81 | GAA (0.44) | ALDH1A1SMN1; SMN2LMNAMAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | claimed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | claimed |
| EP-3687538-B1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INST (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2024-03-19 | — | — | US | disclosed |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montréal Heart Institute (CA) | 2023-03-23 | — | — | US | disclosed |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | Montréal Heart Institute (CA) | 2022-08-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | MONTREAL HEART INSTITUTE (CA) | 2021-12-02 | — | — | US | disclosed |
| EP-3687538-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | Montreal Heart Institute (CA) | 2020-08-05 | — | — | EP | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369688-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | SMPD1 405/4885HTT 3832/4885ALDH1A1 568/4885 |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | SMPD1 2235/4885HTT 4788/4885ALDH1A1 334/4885 |
| US-11931348-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | SMPD1 405/4885HTT 3832/4885ALDH1A1 568/4885 |
| US-20230088095-A1 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | CETP, LDLR, APOB | SMPD1 405/4885HTT 3832/4885ALDH1A1 568/4885 |
| US-11400082-B2 | Methods of treating elevated plasma cholesterol | CETP, LDLR, APOB | SMPD1 405/4885HTT 3832/4885ALDH1A1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.